Revolution Medicines (RVMD) Assets (2019 - 2026)
Revolution Medicines' (RVMD) quarterly Assets came in at $2.3 billion in Q1 2026, down 4.72% year-on-year from $2.4 billion in Q1 2025, and down 4.28% quarter-over-quarter from $2.4 billion in Q4 2025.
Revolution Medicines (RVMD) Assets (2019 - 2026) Analysis & Trends
Revolution Medicines' Assets history runs 8 years deep, the most recent figure standing at $2.3 billion for Q1 2026.
- On a quarterly basis, Assets fell 4.72% year-over-year to $2.3 billion in Q1 2026; TTM through Mar 2026 was $2.3 billion, a 4.72% decrease from a year earlier, with the FY2025 full-year figure at $2.4 billion, down 7.97% from the prior year.
- Assets slipped to $2.3 billion in Q1 2026 per RVMD's latest filing, from $2.4 billion in the prior quarter.
- Across five years, Assets topped out at $2.6 billion in Q4 2024 and bottomed at $55.9 million in Q2 2024.
- The 5-year median for Assets is $1.8 billion (2024), against an average of $1.5 billion.
- Across the five-year window, Assets sank 94.79% in 2024 and jumped 4246.28% in 2025, its largest moves.
- Year by year, Assets stood at $811.9 million in 2022, then jumped by 153.93% to $2.1 billion in 2023, then climbed by 24.09% to $2.6 billion in 2024, then decreased by 7.97% to $2.4 billion in 2025, then dropped by 4.28% to $2.3 billion in 2026.
- Per Business Quant, the three latest RVMD Assets figures stand at $2.3 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 78.88 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 33.89 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 8.55 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.25 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.25 Bn |
| Dec 31, 2025 | 2.35 Bn |
| Sep 30, 2025 | 2.25 Bn |
| Jun 30, 2025 | 2.43 Bn |
| Mar 31, 2025 | 2.37 Bn |
| Dec 31, 2024 | 2.56 Bn |
| Sep 30, 2024 | 1.76 Bn |
| Jun 30, 2024 | 55.90 Mn |
| Mar 31, 2024 | 1.91 Bn |
| Dec 31, 2023 | 2.06 Bn |
| Sep 30, 2023 | 984.23 Mn |
| Jun 30, 2023 | 1.07 Bn |
| Mar 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 811.93 Mn |
| Sep 30, 2022 | 825.91 Mn |
| Jun 30, 2022 | 632.80 Mn |
| Mar 31, 2022 | 682.77 Mn |
| Dec 31, 2021 | 737.99 Mn |
| Sep 30, 2021 | 734.98 Mn |
| Jun 30, 2021 | 774.05 Mn |